A scalable method for molecular network reconstruction identifies
  properties of targets and mutations in acute myeloid leukemia by Ong, Edison et al.
	   1	  
A scalable method for molecular network reconstruction identifies 
properties of targets and mutations in acute myeloid leukemia 
 
 
Edison Ong1, Anthony Szedlak2, Yunyi Kang3, Peyton Smith1, Nicholas Smith1, Madison 
McBride3, Darren Finlay3, Kristiina Vuori3, James Mason4, Edward D. Ball5, Carlo 
Piermarocchi2*, Giovanni Paternostro3* 
 
 
1Salgomed Inc., Del Mar, CA 92014 
2Department of Physics and Astronomy, Michigan State University, East Lansing, MI 
48824 
3Sanford-Burnham Medical Research Institute, La Jolla, CA 92037 
4Scripps Health, San Diego, CA 92121 
5University of California, San Diego Moores Cancer Center and Department of Medicine, 
La Jolla, CA 92093 
 
* Corresponding authors: piermaro@msu.edu and giovanni@sanfordburnham.org 
  
	   2	  
 
ABSTRACT 
 
A key aim of systems biology is the reconstruction of molecular networks, 
however we do not yet have networks that integrate information from all datasets 
available for a particular clinical condition. This is in part due to the limited scalability, in 
terms of required computational time and power, of existing algorithms. Network 
reconstruction methods should also be scalable in the sense of allowing scientists from 
different backgrounds to efficiently integrate additional data.  
We present a network model of acute myeloid leukemia (AML). In the current 
version (AML 2.1) we have used gene expression data (both microarray and RNA-seq) 
from five different studies comprising a total of 771 AML samples and a protein-protein 
interactions dataset. Our scalable network reconstruction method is in part based on the 
well-known property of gene expression correlation among interacting molecules. The 
difficulty of distinguishing between direct and indirect interactions is addressed 
optimizing the coefficient of variation of gene expression, using a validated gold 
standard dataset of direct interactions. Computational time is much reduced compared 
to other network reconstruction methods. A key feature is the study of the reproducibility 
of interactions found in independent clinical datasets.  
An analysis of the most significant clusters, and of the network properties 
(intraset efficiency, degree, betweenness centrality and PageRank) of common AML 
mutations demonstrated the biological significance of the network. A statistical analysis 
of the response of blast cells from eleven AML patients to a library of kinase inhibitors 
provided an experimental validation of the network. A combination of network and 
experimental data identified CDK1, CDK2, CDK4 and CDK6 and other kinases as 
potential therapeutic targets in AML. 
 
The most updated version of the AML network can be found at 
www.leukemianetworks.org 
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INTRODUCTION 
 
The knowledge of genomic changes and of other “omic” alterations in patients 
with acute myeloid leukemia (AML) has increased significantly over the last decade (1, 
2). This has not, however, resulted in the development of new effective therapies and 
AML still has an unfavorable prognosis for most patients (1). Robert Weinberg, one of 
pioneers of the reductionist molecular approach to cancer research (3), recently 
suggested that new data-rich approaches are needed to address the complexity and 
heterogeneity of cancer. He, however, also pointed out that systems biology has not yet 
led to major advances in the understanding and treatment of malignant neoplastic 
disease. 
 A key aim of systems biology is the reconstruction of informative molecular 
networks and it is becoming clear that only cell-specific and disease-specific networks 
are potentially able to benefit medical practice (4 , 5). These networks could be used, 
for example, to obtain actionable information from the complex and often unique 
mutational cancer profiles that sequencing data provide (2). 
More than one million gene expression datasets are available in public 
repositories (6) and biology is clearly ready for the Big Data computational approaches 
that are increasingly used in other fields of science and technology (7, 8). We do not yet, 
however, have disease-specific networks that integrate information from most available 
datasets. This is in part due to the limited scalability, in terms of required computational 
time and power, of existing algorithms. 
 It is also becoming clear that integrating the growing number of datasets and the 
increasing amount of knowledge for a particular pathology is not a realistic task for 
individual research groups or even companies. Network reconstruction methods should 
therefore also be scalable in another sense: they should allow scientists from different 
groups and background to efficiently integrate additional data and progressively 
increase the network accuracy. 
In the version of the AML network we describe here (version 2.1) we have used 
gene expression data (both microarray and RNA-seq) from five different studies (9-13) 
comprising a total of 771 AML samples. We also integrate a human protein-protein 
interactions dataset (14). 
The method we present is in part based on the well-known property of gene 
expression correlation among interacting molecules in biological networks (15). A 
potential problem is the difficulty of distinguishing between direct and indirect 
interactions. We suggest a solution based on the optimization of a statistical property, 
the coefficient of variation, using a validated “gold standard” dataset of direct 
interactions. We show that computational time is much reduced compared to other 
network reconstruction methods and that adding new datasets is especially easy 
because most computations already performed do not need to be repeated. We also 
suggest statistical measures that can provide the optimal correlation coefficient cutoff 
for the selection of significant interactions. A key feature of the method is “overlap 
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analysis”, which is based on the study of reproducibility of interactions found in two or 
more independent clinical datasets.  
 An analysis of the most important clusters, and of the network properties of 
receptors and of common AML mutations demonstrates the biological significance of 
the network. The network properties of kinases are consistent with a statistical analysis 
of the experimental response of AML primary patient cells to a kinase inhibitor library 
and the two measures can be combined to identify potential targets for therapeutic 
interventions. 
 
 
MATERIALS and METHODS 
 
AML Molecular Network Reconstruction 
Figure 1 shows the main modules of the procedure used to generate the AML 
molecular network (AML version 2.1) (more details of the integrations of the modules 
are shown in Figure 1S). The method consists of five major sections, indicated by 
different colors as step I to V: (I) Data Processing, (II) Optimization and Method 
Selection, (III) Transcription Factor-Gene (TFG) Subnetwork Reconstruction, (IV) 
Protein-Protein Interaction (PPI) Subnetwork Reconstruction and (V) Full AML 
Molecular Network. The TFG subnetwork is composed of transcription factors (TFs) and 
their targets, while the PPI subnetwork contains interactions between proteins. The TFG 
and PPI subnetworks were constructed using the five individual expression profiles 
described in the next section and later integrated to form the full AML molecular network. 
The resulting network is a partially directed network. The most updated version of the 
AML network can be found at www.leukemianetworks.org 
 
Data Processing 
The data processing step is indicated as step I (with yellow coloration) in Figure 1. 
Three AML microarray datasets (9-11) were downloaded from the Gene Expression 
Omnibus (GEO) database as raw data (CEL files) and processed using the threestep 
function of the affyPLM R package with default settings. Median gene expression was 
used whenever multiple probes were mapped to a single gene. Two AML RNA-seq 
datasets (12, 13) were downloaded from GEO and from The Cancer Genome Atlas 
(TCGA, downloaded from the TCGA Data Portal on February 11, 2014) databases in 
the RPKM (reads per kilobase per million) format. Genes with RPKM below 1 were 
excluded and a logarithmic transformation was then used. A total of five different 
expression datasets were used. The five expression datasets were used to create five 
TFG and five PPI lists of interactions as described below and were later integrated in 
the TFG and PPI subnetworks. 
 
Optimization and Method Selection 
Optimization and method selection is indicated as step II in orange in Figure 1. A 
key assumption of the optimization and method selection procedure is that the number 
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of experimentally validated interactions (expressed as a ratio of the total number of 
interactions inferred) should be maximized. We used this assumption to establish 
criteria for noise filtering, cutoffs, and consistency checks for networks obtained from 
different datasets and different inference methods. For this purpose, we used the 
TRANSFAC database (version 2013.2) (16) as a “gold standard” of experimentally 
validated interactions and focused on a subset of interactions involving 90 transcription 
factors randomly selected among those present in the five AML expression datasets (9-
13) and their targets. 
A total of 2486 interactions and 1273 targets were found for these 90 
transcription factors (see Table 1S) in TRANSFAC. These 2486 TRANSFAC 
Interactions (TIs, they can also be considered as “True Interactions”) are experimentally 
validated in humans (17) and we used them as a “gold standard” in Optimization and 
Method Selection and TFG Subnetwork Reconstruction. All genes present in these TIs 
were selected from the expression datasets and five test expression profiles were 
created. These test expression profiles were used for the coefficient of variation (CV) 
optimization and for the methods comparison.  
The CV is the standard deviation divided by the average of the expression of a 
gene across all experiments in one dataset. Eliminating genes with low CV removes 
noise, filtering out genes with low variation in their expression. Figure 2 (panel B) shows 
an example of the type of data that were removed. To determine an optimal value for 
the CV cutoff, we maximized the number of “gold standard” TIs found within the top 100 
most significant interactions found by four well-known network inference methods. The 
four methods are ARACNE (18, 19), TIGRESS (20), GENIE3 (21) and Pearson 
Correlation (implemented in Python Scipy) (15). Figure 2 (panels C and D) shows an 
example of this optimization procedure. 
Interactions inferred by these four methods were compared and their TI content 
(expressed as a ratio) is reported in Table 2S. The number of TIs found by using one of 
the other three methods after the Pearson Correlation approach is also reported in 
Table 2S. Note also that transcription factors usually promote expression of their targets, 
so expression values of proteins with this functional relationship should be positively 
correlated. We did, in fact, find an enrichment of the number of TIs (that is, validated 
transcription factors and their targets) for higher Pearson Correlation values (see Figure 
3). 
A run-time analysis was done for the four methods and, besides correlation, the 
other three methods were run using published software (19-21). The run-time analysis 
was done on a system with a AMD FX-4130 quad-core 3.80GHz processor and 32GB 
RAM. For this analysis we used the expression results from Eppert et al (9) as the 
testing dataset. Two variables, number of interactions and number of experiments, were 
used to measure how the size of the dataset affects the run-time (see Figure 2S). The 
interaction number was measured at a constant ratio, where the number of targets was 
10 times more than the number of transcription factors (TFs), which is the approximate 
ratio in human cells (22).  
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Based on these analyses, the Pearson Correlation method was selected for the 
TFG and PPI subnetworks reconstruction. 
 
TFG Subnetwork Reconstruction 
The steps for reconstruction of the TFG subnetwork are shown as step III in blue 
in Figure 1. Optimized CV cutoffs obtained as explained in the previous section were 
used to create five expression profiles. Animal TFDB (23) and KEGG (24) were used to 
obtain the list of known transcription factors (1595 TFs) (Table 1S). Five TFG lists of 
interactions were inferred from the five expression profiles using Pearson’s correlation 
and were ranked based on their correlation coefficients.  
We then partitioned all the interactions in bins of equal size 𝑁! corresponding to 
different intervals of the correlation coefficient. To estimate the significance of the 
interactions in a given correlation interval we considered as a control the case in which 
the 𝑁! interactions are chosen randomly from a pool of  𝑁 possible interactions, and we 
calculated the probability of finding a certain number of TIs (the previously described 
“gold standard” TRANSFAC Interactions). Assuming a statistical model with 
replacement, we can estimate the probability that a TI is found by chance as 𝑞 = 𝑁!/𝑁, 
where 𝑁! is the number of TIs. The probability that the bin finds 𝑘 true interactions by 
chance is then 𝑃 𝑘 = 𝑞!(1− 𝑞)!!!! 𝑁!𝑘 , which can be approximated by a Poisson 
distribution 𝑃 𝑘 = !!! 𝜆 !𝑒!!  where 𝜆 = 𝑁!𝑞 since 𝑁! ≫ 1 and 𝑞 ≪ 1. 
The Poisson statistics was then used to determine the cutoff for the correlation 
coefficient. Figure 3A shows how the procedure was used for one of the datasets. The 
interactions were ranked according to the correlation coefficient and subdivided in bins 
containing the same number of interactions. Bins are ordered in Figure 3A according to 
the correlation coefficient values of the interactions they include decreasing from left to 
right. We then counted the number of TIs in each bin (this number is shown in the 
vertical axis in Figure 3A). In these bins we have 6000 interactions and in the random 
case we would expect an average of 𝜆 = 2 TIs. Using the Poisson distribution, the 
probability of having more than 3 TIs in a bin is less than 0.1 (Figure 3S shows the 
details of this distribution). To determine the cutoff we simply examine each bin from left 
to right and stop before the first bin with 3 or less TIs. The vertical red line in Figure 3A 
shows this cutoff. 
As shown in Table 3S, the bin size and significance level for the cutoff were 
optimized by examining the effects on the overlap analysis, which will be described in 
detail in the next section. Briefly, we identified the parameters that maximized both the 
number of interactions shared by different datasets (we refer to these shared 
interactions as overlaps) and the number of TIs in these sets of overlapping interactions. 
As in our procedure, it is common for the initial steps of a search considering 
multiple factors to select broad sets. An example of this is the implementation of web 
search by modern search engines (25). The rationale is that if a factor is not the only 
predictor, implementing it with a stringent cutoff eliminates many potentially useful 
elements (in our case interactions). This is shown by the optimization procedure we 
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have mentioned in the previous paragraph and also by the fact that, as will be seen, 
even the set of interactions shared by all datasets includes interactions with relatively 
low correlation values. Also note that our procedure allows us to choose a different 
value of correlation as cutoff for each dataset and we can therefore take into account 
the possible variations in quality of the datasets. As table 3S shows we were indeed 
able to select more interactions on average from the RNA-seq datasets, which are 
considered to provide higher quality gene expression data compared to microarrays 
(26). 
 
Reproducibility analysis (overlap) 
A key aspect of our procedure takes into account the reproducibility of interaction 
identification from different clinical datasets. The five selected lists of TFG interactions 
were combined into a unique subnetwork. The interactions were separated into five 
groups: those found from one dataset only, those found from two datasets, and so on, 
up to those found in all five datasets. The shared interactions are from now on referred 
to as “overlaps” for brevity and the groups containing interactions shared by the same 
number of datasets are referred to as overlap groups. These overlap groups are shown 
in Table 4S. 
To estimate the significance of the overlaps obtained from the five datasets we 
considered as control the case in which each of the five datasets yields 𝑀 random 
interactions chosen from a pool of 𝑁 > 𝑀 possible interactions. Given one interaction, 
the probability that one dataset randomly finds it is 𝑝 = 𝑀/𝑁, and the probability that 
only one dataset out of five finds it is 𝑃! = 𝑝(1− 𝑝)! 51 . In the general case of 𝑘 
datasets, this probability is 𝑃! = 𝑝(1− 𝑝)!!! 𝑘1 , which gives an estimated number of 
interactions in the first group 𝑁! = 𝑁𝑃!~𝑘𝑀. Similarly, the probability that one interaction 
is found by 𝑗 out of 𝑘 datasets is 𝑃! = 𝑝!(1− 𝑝)!!! 𝑘𝑗  and the number of interactions in 
group 𝑗 is 𝑁! = 𝑁𝑃!~𝑁 𝑘𝑗 !! ! . This expression can be generalized to the case of 
datasets leading to networks with a different number of interactions 𝑀!,𝑀!,… ,𝑀! as 𝑁! = !!!!!!! 𝑀!!𝑀!! …   𝑀!!!!!!!!⋯!!! , where each index 𝛼! runs from 1 to 𝑘. 
The TFG subnetwork was further compared to 100 randomly generated 
subnetworks and the results were very similar to the estimates obtained as described in 
the previous paragraph (Tables 4A and 4B). The randomly generated subnetworks had 
the same number of interactions for each dataset as the TFG.  
Because of our emphasis on reproducibility, only interactions that appeared in 
two or more datasets were selected for inclusion in AML 2.1. Among reproducible 
interactions, all interactions in a group (meaning the four groups composed of 
interactions found from two to five times) were included in the network if the number of 
interactions in the random simulation was less than 1% of the number of interactions 
found in the group. This implies that the number of interactions identified more than 
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once only by random chance was negligible. If, however, the number of random 
interactions was higher than the 1% threshold, then the average correlation coefficient 
distribution was calculated for the random TFG subnetwork. Interactions with correlation 
coefficients below those corresponding to a p-value of 0.005 were removed. This 
method was used to select 6117 out of 17,817 interactions obtained from only 2 
datasets. The average rank by correlation coefficient value was used to order the 
interactions and the top 6117 were selected. This set of interactions had a higher TI 
ratio (more than 3.4 fold higher) compared to those eliminated in the same group with 
overlap 2 (Table 4S).  
We also analyzed 7 more AML microarray datasets (GSE15434, 24006, 33223, 
34860, 21261, 6891, 22845) which will be included in future versions of the network, 
and measured the number of interactions from the overlap 2 group that were replicated 
again when additional studies were added. This analysis, shown in depth in the 
methodological results section, can assist the choice of which interactions to select 
when dataset numbers increase.  
All interactions found by 3 to 5 expression profiles were kept in the TFG 
subnetwork. The edges between TF and their targets were considered as directed. 
 
PPI Subnetwork Reconstruction 
These procedures are shown as step IV in green in Figure 1. Protein-protein 
interactions were downloaded from HIPPIE (14), which is a database of experimentally 
validated protein-protein interactions. The Pearson correlation coefficients of all HIPPIE 
interactions were calculated using the 5 gene expression profiles (9-13) to infer the PPI 
ranked lists of interactions. The same correlation coefficient cutoffs obtained for the 5 
TFG-ranked lists of interactions were also used as the cutoffs for the five PPI-ranked 
lists of interactions. Figure 3B-C shows that an enrichment for validated interactions 
with higher correlation coefficient values is also found for protein-protein interactions 
(see Table 5S), using the HIPPIE database as an independently validated list. These 
findings support our plans to extend to PPI the optimization approach used for TFG, in a 
future version of the network. 
The integration of the 5 individual PPI datasets was done by using a similar 
overlap analysis as that for the TFG subnetwork. No group had a number of overlapping 
interactions in the random simulations that were higher than 1% of the total found for 
that group and therefore all interactions found in 2 to 5 expression profiles were 
selected for the PPI subnetwork. Interaction directionality was introduced, where 
possible, using the Phosphosite and Phosphopoint kinase/target databases (27, 28). 
 
Integration and Analysis of combined AML Network 
By combining the TFG and PPI subnetworks, a partially directed AML molecular 
network was generated and named AML 2.1.  
Networks were visualized and analyzed using Cytoscape (29). The AML network 
was analyzed using the Cytoscape clustering app, ClustViz, which uses the graph 
theoretic method MCODE (30). The clusters were then analyzed with BiNGO (31) for 
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enrichment analysis of gene ontology. Genes were also ranked based on their degree 
and other network measures and characterized by 4 functional categories: TFs, 
metabolic genes, kinases and receptors. Additionally, a metabolic pathway enrichment 
analysis was done using RECON2 (32). A comparison was made between normal 
human hematopoietic cells and AML cells, using ClusViz clusters and RECON2 
pathways. The Fisher’s exact test (from SciPy) was used for this comparison with the 
gene expression data from the Macrae et al. dataset (12), which also contained normal 
control data. 
A mutation subnetwork was created using the commonly mutated AML genes (2) 
that were found in the AML 2.1 network (21 out of 26 were found) and their 
corresponding first neighbors.  
 
 
Definition and Analysis of Network Measures 
The network measures (25) were calculated with the software provided by 
Rubinov and Sporns (33). The definition of clustering coefficient, transitivity, assortativity 
and betweenness centrality in Table 5 are from Rubinov and Sporns (33). Several 
network measures were confirmed using NetworkX (34). The following measures were 
calculated using NumPy and SciPy. For efficiency we introduced a new quantity, the 
intraset efficiency that generalizes the concept of global efficiency (25) for a set of 
nodes. This quantity allows us to test the properties of the set of nodes characterized by 
mutations in the network. 
The global efficiency of a network is defined as 
𝐸!"#$%" = 1𝑛(𝑛 − 1) 1𝑑!"!,!∈!!!!  
where 𝑑!" is the geodesic distance (length of shortest directed path) from node 𝑗 to node 𝑖, 𝑁 is the set of all nodes in the network, and 𝑛 is the number of nodes in the network. 
Note that 𝑑!" = ∞ if no directed path exists from 𝑗 to 𝑖, and that 0 ≤ 𝐸!"#$%" ≤ 1. The 
inverse of the global efficiency gives a measure of the average geodesic distance 
between nodes in the network, with the average giving more weight to small distances. 
Unlike the characteristic path length, the global efficiency is finite for disconnected 
networks and weakly connected directed networks. 
We define the intraset efficiency of a set of nodes 𝑀 as 
𝐸! = 1𝑚(𝑚 − 1) 1𝑑!"!,!∈!!!!  
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where 𝑚 is the number of nodes in 𝑀, and paths from 𝑗 to 𝑖 are allowed to pass through 
any nodes in 𝑁, including those not in 𝑀. This measures how efficiently nodes within 𝑀 
communicate with each other. Because the sum is performed over 𝑀 only, it is a set 
property rather than an average of single node properties. 𝐸! is normalized so that 0 ≤ 𝐸! ≤ 1. 𝐸! = 0 occurs if and only if 𝑑!" = ∞ for all nodes 𝑖 and 𝑗 in 𝑀, and 𝐸! = 1 
occurs if and only if 𝑀 is a clique (all nodes are connected to all other nodes by a 
bidirectional edge). 𝐸! thus measures how tightly connected 𝑀 is. Unlike the clustering 
coefficient, however, the intraset efficiency includes contributions from nodes which are 
separated by a distance of more than one unit. 
Defining 𝑀 to be the set of 21 genes commonly mutated in AML, the intraset 
efficiency was computed for 𝑀 as well as for a control set of 10 million randomly 
generated sets of 21 genes. 𝐸! was found to be 0.2979, 1.8% larger than the largest 
intraset efficiency of the random sets observed and 145% larger than the mean. A skew 
normal probability distribution was fitted to a histogram of the randomized sets with 𝑅! = 0.999982, and an approximate right-tailed p-value of 7.3×10!! was obtained for 𝐸!. A more conservative estimate of the p-value was obtained by assigning a random 
direction to each protein-protein interaction whose true direction is unknown (rather than 
using an undirected edge). Adding edges to a network guarantees an increase in the 
global efficiency as well as the average intraset efficiency. The genes in 𝑀 
communicate with their neighbors predominantly through protein-protein interactions, 
and some of the PPI edges are listed as undirected in the AML 2.1 network because 
their true directions are unknown. To ensure that these undirected edges were not the 
sole cause of the statistical significance of 𝐸!, a new network was constructed in which 
each undirected PPI edge was assigned a random direction. The significance of 𝐸! was 
then calculated from the new network using 10 million random sets of 21 nodes as a 
control. Only 63 of these sets had intraset efficiencies greater than 𝐸!, which gives an 
estimated p-value of 63/10! = 6.3×10!! . Calculating the p-value using this method 
does not assume a specific form for the distribution of intraset efficiencies. 
 
 
Response of primary AML cells to a library of kinase inhibitors 
The viability response to kinase inhibitors of primary AML samples obtained from 
two clinical centers (Scripps Health and UCSD Moores Cancer Center) was studied 
varying several steps of the experimental approach. This has the advantage of not 
limiting the relevance of our findings to only one set of experimental conditions. 
Leukemia cells were obtained from patients with newly diagnosed or relapsed 
AML under IRB-approved protocols and with informed consent.  Mononuclear cells from 
the samples were isolated by centrifugation through Ficoll-PaqueTM PLUS (17-1440-02, 
GE Healthcare) exactly as per manufacturer’s instructions. For both sets of clinical 
samples the same EMD kinase inhibitor library (EMD Millipore), composed of 244 
inhibitors, was screened for its cytotoxic effects on the AML patient cells.  
The isolated patient cells were plated at a density of 8000 or 25000 cells/well in 
384-well plates (Greiner Bio-One) in RPMI-1640 (Hyclone) supplemented with 10% fetal 
bovine serum (FBS, Hyclone), 100 U ml-1 penicillin, and 100 µg ml-1 streptomycin or in 
mTeSR1 (STEMCELL Technologies). Subsequently, the cells were treated with the 244 
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library compounds at 1.25 microM or 10 microM final concentrations, and cultured in a 
humidified 5% CO2 atmosphere for 72 or 96 hours. At the end of the culture, cell 
viability was measured either using the ATPlite assay (PerkinElmer) or using the 
equivalent CellTiterGlo (Promega) according to the manufacturers’ protocols. 
Luminescence was read using the Analyst HP (Molecular Devices) or BioTek Synergy2 
plate readers.  
 
 
Regression analysis with KIEN 
We have recently developed a method (35) that integrates information contained 
in drug-kinase profiling with in vitro screening. The method uses the in vitro cell 
response of single drugs as a training set to build linear and nonlinear regression 
models. For each kinase, the regression provides a coefficient score 𝛽! measuring the 
sensitivity of cells to alterations in the activity of that kinase. We have explored the 
correlation between this 𝛽!  coefficient and three measures of centrality (degree, 
betweenness centrality and PageRank) for the same kinases according to the AML 2.1 
network topology. The calculation of the 𝛽!  coefficients used the drug response 
screening from a library of 141 kinase inhibitors measured on primary cells from eleven 
AML patients and drug kinase profiling data from a published database (36). The in-vitro 
drug response data from the eleven patients were averaged in the analysis. We 
calculated Pearson Correlation and Spearman Rank Correlation on a set of 101 kinases 
with positive 𝛽! present both in AML 2.1 and in the profiling dataset. The 𝛽! coefficients 
obtained from this analysis are given in supplementary Table 9S. 
 
Supplementary data and software are available at www.leukemianetworks.org 
 
 
RESULTS 
 
Methodological Results 
 
The details of the datasets we used and the corresponding numbers of genes are 
shown in Table 1. Table 1S also shows the number of interactions included in AML 2.1 
obtained from each of the five gene expression datasets. As expected from the more 
quantitative nature of RNA-seq, the datasets obtained with this technique were more 
informative, providing more reproducible interactions compared to the three microarray 
datasets, even when the number of samples was comparable or lower. 
Table 2 shows that the optimized CV cutoff increased the number of validated 
TRANSFAC interactions (TI hits) identified in almost all cases and specifically in every 
case where Pearson Correlation was used. Interactions were ordered according to the 
measurements provided by each method, and the significance of the CV cutoff was 
tested using the two-tailed student t-test of the top 100 and top 1000 interactions, before 
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and after CV cutoff. The CV cutoff in both top 100 and top 1000 resulted in significant 
increases in TI hits with p-value < 0.0001. 
The run times of our optimized Pearson Correlation method and of three 
previously published network reconstruction methods, ARACNE (18, 19), TIGRESS (20) 
and GENIE3 (21), were estimated using the same hardware and datasets and are 
shown in Figure 2S. The comparison shows a speed advantage of several orders of 
magnitude for the optimized Pearson Correlation method we present here. Adding 
another method after optimized correlation identifies 11-15 % more interactions (Table 
3). As shown in Table 2S, however, these interactions are not the same for every 
method added. Figure 4S shows an example of a non-linear relationship that has been 
identified as a network interaction by the three additional methods listed in Table 3, but 
not by our method. As indicated in Table 3 these methods can miss an even larger 
number (14-60 %) of validated interactions found by optimized correlation. 
 
Reproducibility Results (Overlap) 
 Table 4 shows that the reproducibility of our method (measured by the number of 
interactions found in more than one expression dataset) is much higher than that of 
randomly generated TFG and PPI subnetworks. The probability of finding the number of 
interactions reported 2 or more times is much lower than 0.01 for both the TFG and the 
PPI subnetworks. Random simulations and the exact method described in the “overlap 
analysis” section of the Methods provide similar estimates. None of the interactions 
found in only one gene expression dataset are included in the AML 2.1 network. 
In addition to the reproducibility (overlap) of interactions, the TI ratio, defined as 
the number of TIs/number of interactions, was also examined, as shown in Table 3S for 
the TFG subnetwork. This ratio was increased compared to the initial dataset (before 
the application of the optimized correlation selection) even for interactions present in 
only one dataset and increased progressively for those appearing in two or more 
datasets. 
The full lists of overlapping interactions for the TFG and PPI subnetworks are 
shown in Tables 4S and 5S. These tables also show that the average correlation is 
generally higher when the reproducibility increases (we show separately interactions 
found in 1, 2, 3, 4 or 5 datasets) but the distributions of these correlation values are not 
sufficient to separate the groups. In conjunction with the data already referred to in the 
Method section, these findings are consistent with the rationale we have used in the 
optimization of the network. 
We also analyzed 7 more AML microarray datasets (GSE15434, 24006, 33223, 
34860, 21261, 6891, 22845), which will be included in future version of the network, and 
measured the reproducibility of the interactions using all 12 datasets. The data are 
shown in Table 10S.  
Using the 12 datasets we also measured the TI ratio for the first 10 overlap 
groups (the number of interactions was too small in groups 11 and 12). The data are 
presented in Supplementary Table 12S and show a monotonic (exponential) increase of 
the TI ratio with the number of overlaps, and therefore with the reproducibility of the 
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interactions. We found a significant Spearman’s correlation between the group number 
and the TI ratio with p<0.0001. 
Remarkably, a similar increase as a function of the group number is also 
obtained when we measure, as a ratio, the interactions that, for each of the 10 overlap 
groups obtained from an analysis of 10 datasets, were found again twice when two 
more datasets were added. This ratio is a measure of the probability of reproducibility, 
and therefore of validity for interactions in each group, and was found to increase 
monotonically from overlap group 1 to overlap group 10 (Spearman correlation had p 
<0.0001) (Supplementary Table 12S). This probability was found to be well 
approximated by a single-parameter sigmoid function of the form 1+ 𝑒!!! !!  where x 
is the overlap group and the fitting parameter z=6.15609 (R2=0.9986). See Fig. 4A. 
Reproducibility can also be studied within the groups shown in Figure 4A. The 
reproducibility of interactions in the overlap 2 group, ordered by an average rank 
obtained from their correlation coefficient, declined monotonically. We measured the 
interactions in this overlap 2 group that were found again after adding all possible 
combinations of two more datasets. Each of the interactions originally found in 2 
datasets could now therefore remain in overlap group 2 or could be found in overlap 
groups 3 or 4. Assigning a value of 1 to those that progressed one step to group 3 and a 
value of 2 those that progressed two steps to group 4 the average score for the top 
6000 interactions was 0.268 while for the remaining interactions in the group it was only 
0.068, a decrease of almost 4-fold. This difference was highly statistically significant, 
using both a parametric and a non-parametric test (p<0.0001 with the Mann Whitney 
test). 
We also studied this behavior in additional overlap 2 groups for datasets 6 to 10 
and identified an exponential fitting that can be used to predict the distribution of the 
probability of reproducibility after the addition of two more datasets, as a function of the 
rank of an interaction within a group (Supplementary data and Figure 4B). The 
probability distribution is well approximated by 𝑃 𝑅, 𝑘 = 𝑎𝑒!!/!(!) where R is the rank 
of the interaction within the group, and Q(k) is a characteristic decay rank that depends 
on the number of datasets k. The factor a takes into account the probability distribution 
normalization. We found that the characteristic decay rank scales with the number of 
possible interactions contained in each group and is well approximated by the relation 𝑄 𝑘 = 515.04 𝑘2  (𝑅! = 0.998). Figure 4B shows that the correlation-based ranking 
within group 2 contains less information and is less significant when more datasets are 
added, since the top ranking interactions in this group become less reproducible. 
These models and analyses can assist the choice of which interactions to select 
when the number of datasets increases and could also be used to build weighted 
networks.  
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Biological Results 
 
Properties, Visualization and Gene Ontology cluster analysis of AML 2.1 
The full list of TFG and PPI interactions in AML 2.1 is shown in Table 6S. The 
global network properties of AML 2.1 are shown in Table 5 (25). The AML 2.1 network 
contains the TFG and PPI subnetworks and is partially directed. MCODE clustering 
analysis found a total of 101 clusters. The complete list of clusters is shown in Table 7S. 
Table 6A also shows the differences between normal human hematopoietic cells and 
AML patients for the top 13 clusters, with corresponding GO (Gene Ontology) functional 
terms, and the p-values for these differences. The Fisher’s exact test and false 
discovery rate (FDR) were performed on the clusters and 4 clusters were found to be 
expressed with a p-value <0.1 in either Normal subjects or AML patients. Two clusters 
related to immune response and cell cycle were found to be highly expressed in AML 
patients. On the other hand, one cluster related to translation and biosynthetic process 
was found to be highly expressed in normal human hematopoietic cells. Figure 5 shows 
the AML 2.1 network with the top MCODE clusters. Figure 5 also shows several other 
functions that are relevant to the cells of origin of AML, for example “Leukocyte and 
Lymphocyte activation”. Table 6B shows similar comparisons using Fisher’s exact test 
with RECON2 (32) metabolic pathway clustering. Eight RECON2 pathways were found 
to be differentially expressed. 
 
Receptors 
We also examined the number of interactions for specific functional classes, 
including cellular receptors. The two most connected receptors, with degree (number of 
connections) higher than 200 were VDR (vitamin D receptor) and RXRA (retinoid X 
receptor, alpha) (Table 8S). As we mention in the Discussion these are known to have 
important roles in AML cells. We have also analyzed the two human AML RNA-seq 
datasets we use in this study (12, 13) and found that the coefficient of variation of 
receptors expression between different patients is in both cases approximately double 
that of other genes (p<0.0001). 
 
AML Mutations  
The network is significantly enriched for common known AML mutated genes. It 
contains 21 out of 26 significantly mutated AML genes (2) even though it is composed 
of only 5667 genes/proteins  (p = 2.3x10-8 for the enrichment). This shows that the 
network reconstruction method enriches for functionally relevant genes. Figure 6 shows 
the 21 common AML mutations included in the network and their first neighbors. This 
sub-network is highly connected with a total of 5 clusters and with the largest cluster 
containing 16 AML mutated genes. Figure 7 shows the mutations and their first 
neighbors within the AML 2.1 network. Comparing Figures 5 and 7 shows that the 
mutations co-localize with functional clusters of known relevance to cancer, including 
“cell cycle” and “DNA replication”. 
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To examine the statistical significance of these measures, random subnetworks 
were generated. Random subnetworks consisting of 21 random genes and their first 
neighbors were less connected than the mutation subnetwork. They had an average of 
16.2 clusters and an average size of 3.5 genes from the group of 21 in the largest 
cluster (p<0.0001 compared to the mutation subnetwork). Other network measurements 
were also computed with the same random subnetwork simulation, as shown in Table 7 
and Supplementary figure 7S. The 21 mutations also had significantly higher values of 3 
network centrality measures: degree (p = 0.015), betweenness centrality (p = 0.02) and 
PageRank (p = 0.01) (25).  
A similar conclusion, with stronger statistical significance, is obtained by 
examining the intraset efficiency for the 21 mutations and for random sets of 21 genes.  
The intraset efficiency was clearly higher for the set of 21 mutations. Figure 8 shows 
that a skew normal probability distribution was fitted to a histogram of the randomized 
sets with 𝑅! = 0.99, and an approximate right-tailed p-value of 7.3×10!! was obtained. 
This measure indicates that the paths among the mutations are much shorter than for 
control sets. In other words the mutations can more easily exchange information. 
As shown by visual inspection and comparison of Figures 5 and 7 and by 
calculating the clustering coefficient (table 7 and Figure 7S) the mutations do not, 
however, form a tight cluster. That is, they do not interact mainly among themselves.  
Table 8 shows a summary of the GO functional enrichment analysis of the 
mutation subnetwork, obtained using DAVID (37). The full analysis is shown in Table 8S. 
The mutation subnetwork is composed of 21 common AML mutations and of their first 
neighbors, for a total of 257 genes, but a very similar list of GO terms is obtained by 
analyzing the first neighbors only (Table 8S), showing that the functional information is 
contained in the network and not only in the mutations. These functions are those 
commonly associated with cancer mutations, including DNA replication, cell cycle and 
cell death. 
 
Experimental validation using kinase inhibitors and AML primary samples 
Centrality measures can be used to rank kinases in AML 2.1. These results were 
compared to the response of AML primary cells to a library of 244 kinase inhibitors. A 
method we have recently developed, based on elastic net regression applied to kinase 
inhibitors, the KIEN method (35), was used to identify and rank according to a score 𝛽! 
(see Methods), the kinases responsible for the effects of the kinase inhibitors in primary 
AML cells from eleven patients.  
We then calculated Pearson Correlation and Spearman Rank Correlation on a 
set of 101 kinases present both in AML 2.1 and in the drug response dataset (see 
Methods). Table 9A shows the correlation coefficients and significance values of 
betweenness centrality, degree, and PageRank with the KIEN parameter 𝛽! , using 
Pearson and Table 9B shows the same three correlations using Spearman Rank 
Correlation. Betweeness centrality is significantly correlated with 𝛽! according to both 
methods while degree and PageRank were significant only with Pearson Correlation. A 
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plot of the 𝛽! versus the three centrality measures for the 101 kinases used in this 
analysis is provided in the Supplementary Figures. 
The top 10 kinases identified by the combined use of betweenness centrality, 
and PageRank with KIEN are shown in Tables 10 and 11. The most remarkable finding 
is the presence of a group of four kinases, CDK1, CDK2, CDK4 and CDK6 at the top of 
the independent analyses based on AML 2.1 centrality measures and on experimental 
data analyzed by KIEN (with significance of p < 10-7 for betweenness centrality, 
PageRank and also degree, the details of the degree analysis are shown in the 
Supplementary data). The other kinases shown in Tables 10 and 11 are strong 
candidate targets for further experimental studies. 
Specific literature support for the involvement of these targets in AML is analyzed 
in more depth in the Discussion but and additional level of statistical confirmation of our 
approach is obtained by showing that the number of relevant citations for each of the 
101 kinase targets mentioned above in this section (obtained by searching Pubmed for 
the gene name and the term AML) is significantly correlated (using Spearman) with the 
combined average rank of the kinases obtained as shown in Tables 10 and 11. The p 
value is lower than 0.0003 for ranks obtained from all three centrality measures 
(betweenness centrality, degree, and pagerank). 
 
DISCUSSION 
We have developed a fast, reproducible and scalable network reconstruction 
method, which is able to integrate biological datasets of different types. In the AML 2.1 
network version we present here, both microarray and RNA-seq gene expression data 
and protein-protein interaction data were included. 
Only interactions derived from at least two independent clinical datasets were 
selected for the network and some of the interactions found twice underwent further 
filtering. This is the only strategy that can correct for all possible types of noise, 
including biological, clinical and experimental variation. As can be seen from Table 4, 
this led to pruning of a large number of interactions, and, most likely, to a higher quality 
AML network. The alternative approach of pooling all the data and performing a single 
analysis would be much less tractable computationally, would be less efficient when a 
new dataset is added, would pose severe problems of normalization among studies and 
would be more prone to artifacts, because a small number of data points can greatly 
affect the correlation coefficient. Even in fields as diverse as particle physics (38, 39) 
and clinical drug development (40-43) performing multiple studies is considered a 
source of stronger evidence compared to pooling all resources in a single giant study. 
The analysis of reproducibility in different datasets, which we call “overlap 
analysis”, can also provide a quantitative estimate of the probability of an interaction, 
based on the number of datasets in which it has been found. Figure 4B shows that 
within a group with the same reproducibility measure (that is containing interactions 
found in the same number of datasets) the value of the correlation coefficient for an 
interaction could predict the probability of being identified again when additional 
datasets were analyzed. As shown in Figure 4A, the same was true when comparing 
different groups. It is therefore clear that determining which interactions to include in the 
network is a trade-off between maximizing the confidence in the included interactions 
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and building a network too sparse to have sufficient statistical power for meaningful 
analysis. The use of a weighted network is an alternative strategy that might allow the 
appropriate inclusion of a larger number of links (44). 
The clustering analysis identified gene functions that are consistent with the 
tissue of origin of AML. The differences of AML vs normal cells gene expression for 
these clusters was also in the expected direction, for example glycolysis is well-known 
to be up-regulated in cancer cells. 
Among the findings supporting the biological relevance of AML 2.1 are the 
observations that the network is significantly enriched for common known AML driver 
mutated genes (2) and that the mutation subnetwork is enriched for important cancer-
related functions. Most notable among these are cell cycle related genes, presently one 
of the most active fields of drug development in many cancer types (45, 46).  
The network properties of AML mutations we report are potentially useful for the 
understanding and therapy of cancer. It seems that mutated cancer genes not only are 
related to the functional categories we know well (47) but also have network properties 
of efficient communication among the set and of centrality, therefore being able to 
influence many other cell functions. They do not form a close cluster, where the genes 
preferentially interact only among themselves. The centrality findings we obtained are 
consistent with previous reports of the relevance of PageRank network measures to the 
identification of cancer biomarkers (48). 
The targets shown in Tables 10 and 11 were identified using both the AML 2.1 
network properties and the KIEN analysis of experimental drug response data from AML 
primary cells. The four targets with higher statistical significance were CDK1, CDK2, 
CDK4 and CDK6. CDK 4/6 inhibitors have been shown to be effective in phase II cancer 
clinical trials, some of which were presented at the ASCO and AACR 2014 meetings 
(49). One of these CDK 4/6 inhibitors, palbociclib, has received the “breakthrough 
therapy” designation by the FDA (50), which is intended to lead to accelerated approval. 
Several papers have also shown that CDK inhibitors are effective in AML cells (51-54). 
The other targets shown in Tables 10 and 11 have also all been previously linked 
to AML and, in some cases, to cell cycle genes.  LCK and LYN are part of the SRC 
family and CSK is a kinase acting on SRC.  SRC family kinases have been implicated in 
AML by several authors (55, 56) and are targets of Dasatinib, which has been shown to 
be active on AML cells (57). LCK is also known to interact with and being 
phosphorylated by CDK1 (58). TYRO3 expression has been associated with AML (59) 
and the expression of his ligand identifies high-risk AML patients (60). CHEK1 is 
another important cell cycle gene and suggested target for cancer therapy (61), which 
has been shown to sensitize AML cells to cytarabine action in an RNAi screen (62). 
CHUCK (also known as IKK-alpha) is part of the cell cycle regulatory network together 
with CHEK1 (63) and also contributes to the regulation of cell death in AML cells (64). 
RPS6KA1 has been suggested as one of the mediators of the anti-apoptotic action of 
FLT3, one of the main AML mutations (65). Finally MAP2K2 (also known as MEK2) has 
a very important role in regulating CDK4/6 activity (66) and is often activated in AML 
cells (67). 
The potential of the combined use of AML 2.1 analysis and KIEN is not simply to 
provide a list of a few targets to be completely inhibited. We can actually identify the 
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optimal amount of inhibition of each target, which corresponds to the coefficients of the 
KIEN regression equation, for a large number of kinases. This can potentially lead to the 
type of precise and robust distributed control that is common in biology (for example by 
transcription factors or microRNAs (22)) but until now not in pharmacology. The kinase 
response in vitro of primary cells is however in part influenced by the culture conditions, 
which differ from the in vivo microenvironment (68) and obtaining additional 
independent confirmation using the AML 2.1 network properties is extremely useful. 
This combined approach can also be used for personalized therapy. We show 
that useful data using hundreds of kinase inhibitors can be obtained using primary cells, 
and even more precise individual targeting information could be obtained using the 
larger libraries (composed of up to thousands profiled kinases (22)) that several pharma 
companies have at their disposal. This would represent a dynamic molecular profiling of 
leukemic cell response, potentially much more valuable than the static snapshot of 
present omics techniques. The network could also be personalized further, for example 
by using individual gene expression data to prune not significantly expressed gene and 
by giving a greater weight to mutations form a single patient and to their first neighbors 
within the network. An optimal kinase inhibitor combination could therefore be designed 
computationally (35), even in cases when the mutations would not be actionable, and 
then verified further by appropriate systematic testing using patient’s cells (69, 70). 
While our increasing appreciation of the heterogeneity of cancer mutations (71), 
both between and within patients, is a cause of concern for the development of 
generally effective therapies, the identification of their shared pattern of connections 
raises the hope that sufficiently large and precisely calibrated combinatorial therapies 
designed along the principles we have discussed might benefit a wide range of patients. 
The network could also be used to identify the receptors likely to have the largest 
effects on AML cell viability. The most connected receptors include some with well-
known effects in AML cells, supporting the relevance of the network model. Among 
these are several interleukin receptors and the interferon gamma receptor. The top two 
receptors for connectivity (degree) and other network properties are VDR and RXRA. 
The ligands for these receptors, vitamin D3 and retinoic acid, have in fact well-known 
effects on AML cell proliferation and differentiation (72, 73).  
As we mentioned in the Introduction, we suggest that network reconstruction 
should also be socially scalable, in the sense of facilitating the integration of information 
from scientists of different backgrounds. This would be made easier by the adoption of 
the open source model for the continuous improvement of the networks and of the 
related software. Open source software is written by many (up to thousands) volunteer 
computer programmers publicly sharing and reviewing their work in real time as part of 
a self-organized community (74). Several fields of software development have seen the 
emergence of very successful open source approaches (74), for example the operating 
system Linux and the web server application Apache (74). 
We report data comparing the method used for AML 2.1 with other common 
methods for network reconstruction (18-21). It is reasonable to conclude that since all 
methods share most validated interactions found in our test they might considered to be 
roughly equivalent, and it is certainly possible that combining multiple methods might be 
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useful (15, 75). We would need to understand more about the biological significance of 
the interactions that are uniquely found by each method to do a more precise 
comparison. It is also possible that after adding more data all methods will eventually 
find essentially the same set of interactions. It is clear however from the run-time 
analysis (see also Supplementary data) and from considering the computational steps 
each method performs that the method described here is much faster. It has also been 
designed to be especially scalable, because most calculations do not need to be 
repeated when a new dataset is added. In addition, the portion of the method based on 
reproducibility in multiple datasets (the “overlap analysis”) is also applicable to other 
network reconstruction strategies. 
It has been stated by leaders in artificial intelligence and data mining that 
“invariably, simple models and a lot of data trump more elaborate models based on less 
data” (76, 77). Thus a case might be made for considering as our top priority the 
analysis of all existing gene expression datasets with the fastest and most scalable 
method that gives a reasonable performance in network reconstruction. We have shown 
that very useful information can be obtained in a study using only five datasets and it 
seems that we are not doing all we can for cancer patients if we leave existing data 
unutilized. 
Planned future additions to the network include the use of HIPPIE (14), with the 
same optimization role for PPI as that played by TRANSFAC (17) for TFG (expected in 
version 3) and the addition of microRNA/target interactions and of metabolic networks 
(32) (expected in version 4). We also intend to use more AML datasets (potentially all 
published ones) and to explore subtypes of this acute leukemia, including pediatric 
AML. We then plan to extend the approach to other leukemias and eventually to other 
cancers and to other diseases.  It will also be important to develop network models for 
normal cell types to assist the design of selective therapies with reduced toxicity. This 
will allow the development of comparative network analysis. For example, the 
evaluation of the general relevance of the network properties we describe for the AML 
mutations will only be possible when networks for many different cancer types will be 
reconstructed using comparable methods. 
We therefore present a fast and scalable method for the reconstructions of 
intracellular networks that can contribute to the understanding of the network role of 
cancer mutations and to the identification of targets for therapeutic interventions, also in 
combination with complementary statistical analyses of experimental data. 
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FIGURE LEGENDS 
 
Figure 1. Basic workflow to generate the AML network (version 2.1) 
a : Only genes with expression level higher than 1.0 RPKM were selected and then log 
transformation was used to normalize the RNA-seq data.  
b : The Threestep function with default setting from the affyPLM package by 
Bioconductor was used for microarray data processing. Additionally, multi-probe to gene 
mapping used median probe expression. 
c : Four methods were compared: Pearson correlation; Aracne; TIGRESS; GENIE3. 
The methods were compared using run-time simulations and the TRANSFAC 
Interaction (TI) hit rate using test datasets. 
d : The average for the Poisson distribution was 2 TIs per interval. Only interactions 
within intervals with p-value lower than 0.10 were selected for later analysis. 
e, f : Only reproducible interactions were selected. A further selection was based on the 
probability of finding the same interaction multiple times only by random chance. 
 
Figure 2. CV Optimization.  
Panels A and B show an example of a retained gene target (LCK) and of an eliminated 
gene target (GP5) of the same transcription factor (ETS1). GP5 was eliminated from the 
network because of the low coefficient of variation. It s clear that the transcription factor 
is not likely to increase the expression of the target. Panels C and D show an example, 
for one of the datasets (Eppert), of the two-steps optimization, with finer resolution in D. 
The coefficient of variation (CV) value is optimized to give the highest TI rate.  
 
Figure 3. TFG and PPI interactions ranked by correlation values. 
Panel A. Poisson statistic used for the selection of TFG interactions. The Panel shows 
the TI hits used for the Poisson distribution selection in the case of the CV-optimized 
Eppert dataset. Bins are ranked by correlation values, decreasing from left to right. The 
red line indicates the cutoff. Only interactions with correlation values above (to the left of) 
the cutoff were selected.  These correspond to bins with a higher number of TIs, which 
are the validated TRANSFAC interactions. 
Panel B. PPI interactions and HIPPIE hits. The Panel shows the number of HIPPIE 
Interactions hits within 15,000,000 random interactions from the Eppert dataset.  
Panel C.  PPI interactions and HIPPIE hits.  The Panel shows HIPPIE Interactions hits 
within the first bin (50,000 interactions) in A, with finer resolution. Bins are ranked by 
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correlation values decreasing from left to right. The analysis is from a randomly selected 
subset corresponding to about 10% of all possible correlations of the Eppert dataset.  
As for the TFG subnetwork shown in Panel A, also for the PPI subnetwork bins 
corresponding to interactions with a higher correlation coefficient contain a higher 
number of validated interactions obtained from the HIPPIE database. 
 
Figure 4. Reproducibility analysis. 
Panel A: Reproducibility Probability in 10 groups. The figure shows the probability that 
an interaction found in overlap group x (horizontal axis) using 10 datasets is found in 
group x+2 when 12 datasets are used. This probability gives an estimate of 
reproducibility for group 1 to group 10. The 10 points were found to be well 
approximated by a single-parameter sigmoid function of the form 1/(1+Exp(z-x)) where x 
is the overlap group and the fitting parameter z=6.15609 (R2=0.9986).  
Panel B Reproducibility Probability Distribution within group 2. The figure shows the 
distribution of the probability of reproducibility (after the addition of two more datasets) 
as a function of the rank R of an interaction within group 2 with k=5 to 10 datasets. The 
fitting to the probability distribution is of the form P(R,k)=a Exp[-R/Q(k)], where R is the 
rank of the interaction within the group, and Q(k) is a characteristic decay rank that 
depends on the number of datasets k. The factor a takes into account the probability 
distribution normalization. This figure indicates that the correlation-based ranking within 
group 2 contains less information and is less significant when more datasets are added, 
since the top ranking interactions in this group become less reproducible. 
 
Figure 5. AML Network 2.1 with the 13 main clusters.  
AML 2.1 is shown with 13 functional clusters highlighted.  The clusters had significant 
differences between AML patients and controls. See Table 8 for a detailed description 
of the functions associated with each cluster.  
 
Figure 6. Mutation subnetwork.  
This subnetwork is composed of 21 common AML mutations and their first neighbors. 
The red dots are the mutations, the blue dots are their first neighbors, the blue edges 
are TFG interactions and the green edges are PPI interactions. 
 
Figure 7. AML Network 2.1 with the mutation subnetwork.  
AML 2.1 is shown with the 21 common AML mutations and their first neighbors 
highlighted. The red dots are the mutations and the pink dots are their first neighbors. 
The mutation subnetwork overlaps the region where in figure 5 we see the clusters for 
cell cycle, translation and DNA replication. 
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Figure 8. Intraset efficiency.  
The intraset efficiency of the 21 genes commonly mutated in AML cells as well as 10 
million randomly generated sets of 21 nodes for a control. The vertical axis shows the 
probability density. The histogram was built using 50 bins of uniform width. The red 
curve is the right-skewed normal distribution fitted to the random data, which has 𝑅! = 0.999982. The mutation intraset efficiency is greater than the intraset efficiency of 
all random sets examined. 
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Figure 2 
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Figure 5 
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Figure 7 
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Figure 8 
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TABLES 
Dataset Technique GSE ID Number of 
samples 
Full-Size 
Expression 
Profile.  
Number of 
genes 
Test 
Expression 
Profile.  
Number of 
genes 
CV Optimized 
Expression 
Profile.  
Number of 
genes 
Eppert Microarray GSE30377 93 12495 1208 3663 
Metzeler Microarray GSE12417 163 12495 1208 4535 
Valk Microarray GSE1159 293 12496 1208 3388 
Macrae RNA-seq GSE49642 43 11737 785 3154 
TCGA RNA-seq NA 179 12917 881 4332 
Table 1. Expression datasets used for the study, for both the TFG and the PPI 
subnetworks. Three microarray and one RNA-seq datasets were downloaded from GEO. The 
TCGA RNA-seq LAML dataset was downloaded from the TCGA Data Portal. 
	  
	  
Network	  Inference	  
Method 
Data	  
Source Data	  Type 
Top	  100	  TI	  Hit	  
Pre	  CV 
Top	  100	  TI	  Hit	  
Post	  CV 
Top	  1000	  TI	  Hit	  
Pre	  CV 
Top	  1000	  TI	  Hit	  
Post	  CV 
Pearson	  Correlation Eppert Microarray 10 13 61 67 
Pearson	  Correlation Macrae RNA 9 14 44 63 
Pearson	  Correlation Metzeler Microarray 11 19 23 62 
Pearson	  Correlation TCGA RNA 5 18 56 60 
Pearson	  Correlation Valk Microarray 12 22 35 72 
Aracne Eppert Microarray 6 8 45 43 
Aracne Macrae RNA 7 7 28 35 
Aracne Metzeler Microarray 3 14 30 47 
Aracne TCGA RNA 9 11 56 46 
Aracne Valk Microarray 11 17 50 61 
GENIE3 Eppert Microarray 13 16 53 57 
GENIE3 Macrae RNA 11 13 53 59 
GENIE3 Metzeler Microarray 18 18 43 64 
GENIE3 TCGA RNA 13 17 67 61 
GENIE3 Valk Microarray 18 19 54 74 
TIGRESS Eppert Microarray 9 13 43 60 
TIGRESS Macrae RNA 5 8 52 55 
TIGRESS Metzeler Microarray 16 17 38 56 
TIGRESS TCGA RNA 14 15 58 54 
TIGRESS Valk Microarray 14 19 42 70 
Table 2. Number of TI (TRANSFAC interactions) Hits for the top 100 and the top 1000 
interactions. Interactions were ordered by the values provided by the different inference 
methods, before and after the correlation coefficient (CV) cutoff.  The data were obtained using 
the test datasets. The Table shows the increase after the CV cutoff. 
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Method 
TI	  Interactions	  
shared	  with	  
correlation 
TI	  
Interactions	  
unique	  to	  
correlation 
TI	  Discovery	  unique	  
to	  correlation	  -­‐	  Ratio 
TI	  Interaction	  unique	  
to	  other	  method 
TI	  Discovery	  unique	  
to	  other	  method	  -­‐
Ratio 
ARACNE 49 35 0.60 9 0.11 
GENIE3 72 12 0.14 13 0.15 
TIGRESS 65 19 0.24 13 0.15 
Table 3. Additional information provided by the indicated methods compared with 
optimized correlation. The last column shows the ratio of newly identified TIs to those found 
with the correlation method.  This column shows that adding an additional method increases the 
number of validated interactions (TIs) already found with optimized correlation only by 11-15 %. 
The third data column shows the same ratio when optimized correlation is added to one of the 
other three methods. 
	  
	  
	  
Number	  of	  
Datasets	  where	  
an	  interaction	  is	  
present	  
Avg.	  Interactions	  
in	  Random	  
Simulations	  
Interactions	  
in	  Random	  
Model	  
Interactions	  in	  
TFG	  Subnetwork	  
Interactions	  
included	  in	  
AML	  2.1	  
Significance	  
of	  number	  of	  
reproducible	  
interactions	  
1	   179574	   179579	   129943	   0	   NA	  
2	   612	   611	   17817	   6117	   p	  <	  10	  -­‐10	  
3	   1	   1	   2505	   2505	   p	  <	  10	  -­‐10	  
4	   0	   0	   1183	   1183	   p	  <	  10	  -­‐10	  
5	   0	   0	   596	   596	   p	  <	  10	  -­‐10	  
Table 4A. The number of TFG subnetwork interactions that are found in 1 or more 
datasets are compared to those found in randomly generated subnetworks. None of the 
interactions listed in the 1 Dataset row were included in AML2.1. Only part of the interactions 
found 2 times were included. 
	  
	  
Number	  of	  
Datasets	  where	  
an	  interaction	  is	  
present	  
Avg.	  Interactions	  
in	  Random	  
Simulations	  
Interactions	  
in	  Random	  
Model	  
Interactions	  in	  
PPI	  Subnetwork	  
Interactions	  
included	  in	  
AML	  2.1	  
Significance	  
of	  number	  of	  
reproducible	  
interactions	  
1	   45836	   45825	   13754	   0	   NA	  
2	   3	   9	   6794	   6794	   p	  <	  10	  -­‐10	  
3	   0	   0	   2487	   2487	   p	  <	  10	  -­‐10	  
4	   0	   0	   1705	   1705	   p	  <	  10	  -­‐10	  
5	   0	   0	   844	   844	   p	  <	  10	  -­‐10	  
Table 4B. The number of PPI subnetwork interactions that are found in 1 or more 
datasets are compared to those found in randomly generated subnetworks. None of the 
interactions listed in the 1 Dataset row were included in AML2.1. 
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 AML 2.1 
Nodes 5667 
Edges 22218 
Global efficiency 
0.1215	  
Average clustering coefficient 
0.1983	  
Transitivity 
0.2043	  
Assortativity 
-­‐0.2008	  
Betweenness centrality 
0.00054	  
Table 5. Network Properties of AML 2.1. 
	  
	  
Cluster	  ID	   Representative	  GO	  Term	  
Higher	  
Expression	  In	   p-­‐value	  
5	   Immune	  Response;	  Defense	  Response	   AML	   7.07E-18 
2	   Translation;	  Biosynthetic	  Process	   Normal	   8.46E-06 
7	   Cell	  Cycle	   AML	   0.00017 
1	   Transcription;	  Biosynthetic	  Process	   Normal	   0.012 
3	   Immune	  System;	  Leukocyte,	  Lymphocyte	  Activation	   AML	   0.031 
20	   Negative,	  Positive	  Regulation	  of	  Ligase	  Activity	   AML	   0.038 
9	   DNA	  Metabolic,	  Replication	  Process	   Normal	   0.038 
25	   Translation;	  Biosynthetic	  Process	   Normal	   0.039 
10	   Heme	  Biosynthetic	  Process	   Normal	   0.061 
6	   Negative,	  Positive	  Regulation	  of	  Ligase	  Activity	   AML	   0.062 
12	   Regulation	  of	  Actin	  Polymerization	   AML	   0.069 
28	   Cell	  Cycle,	  Division	   AML	   0.069 
30	   mRNA	  Metabolic,	  Transport	   Normal	   0.087 
Table 6A. Top 13 MCODE Clusters (P-value < 0.10). The Fisher’s exact test was used to 
compare the expression profile of AML and normal hematopoietic cells. 
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RECON2	  Pathways	  
Higher	  
Expression	  In	   P-­‐value	  
Oxidative phosphorylation AML	   0.0070 
Heme synthesis Normal	   0.011 
Glycolysis/gluconeogenesis AML	   0.016 
Transport, lysosomal AML	   0.032 
N-glycan synthesis Normal	   0.034 
NAD metabolism AML	   0.038 
Selenoamino acid metabolism Normal	   0.061 
Pentose phosphate pathway AML	   0.065 
Table 6B. Top 8 RECON2 pathways (P-value < 0.10). The Fisher’s exact test was used to 
compare the expression profile of AML and normal hematopoietic cells. 
 
 
 
 
	  
Measurements	  
Mutations	  
Mean	   Control	  Mean	   Control	  Median	   Control	  STD	   P-­‐value	  
Clustering	  
Coefficient	   0.130	   0.198	   0.193	   0.0664	   0.846	  
Local	  Efficiency	   0.202	   0.233	   0.229	   0.0723	   0.648	  
Degree	   27.952	   11.799	   10.619	   5.338	   0.015	  
In-­‐Degree	   13.476	   5.894	   5.476	   2.169	   0.0087	  
Out-­‐Degree	   14.476	   5.905	   4.952	   3.753	   0.0392	  
Betweenness	  
Centrality	   0.00206	   0.0005	   0.0004	   0.0005	   0.0207	  
Eigen	  
Centrality	   0.0027	   0.0017	   0.0003	   0.0028	   0.228	  
PageRank	   10.942	   5.313	   5.0266	   1.631	   0.0125	  
Table 7. Network measures of the 21 AML mutations set compared to controls (random 
gene sets of the same size). 
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GO	  Term Description	   Count PValue Fold	  Enrichment FDR 
GO:0006259 DNA	  metabolic	  process	   43 4.28E-­‐16 4.47 7.55E-­‐13 
GO:0051276 chromosome	  organization	   42 5.06E-­‐16 4.56 9.44E-­‐13 
GO:0006396 RNA	  processing	   42 3.00E-­‐14 4.04 5.08E-­‐11 
GO:0006974 response	  to	  DNA	  damage	  stimulus	   33 7.17E-­‐13 4.66 1.22E-­‐09 
GO:0007049 cell	  cycle	   47 3.29E-­‐12 3.19 5.58E-­‐09 
GO:0033554 cellular	  response	  to	  stress	   39 8.55E-­‐12 3.63 1.45E-­‐08 
GO:0006281 DNA	  repair	   27 2.79E-­‐11 5.00 4.73E-­‐08 
GO:0016568 chromatin	  modification	   23 1.16E-­‐08 4.42 1.97E-­‐05 
GO:0006260 DNA	  replication	   18 1.20E-­‐07 4.99 2.03E-­‐04 
GO:0016570 histone	  modification	   14 5.17E-­‐07 6.04 8.77E-­‐04 
GO:0010941 regulation	  of	  cell	  death	   37 1.69E-­‐06 2.39 0.0029 
GO:0034621 
cellular	  macromolecular	  complex	  
subunit	  organization	   22 4.39E-­‐06 3.24 0.0074 
GO:0045934 
negative	  regulation	  of	  nucleobase,	  
nucleoside,	  nucleotide	  and	  nucleic	  
acid	  metabolic	  process	   27 4.67E-­‐06 2.78 0.0079 
Table 8. GO enrichment analysis for the mutation subnetwork of AML 2.1 (composed of 
21 common AML mutations and their first neighbors, for a total of 257 genes). 
 
 
 
	  
Centrality Measures Pearson Correlation 
Coefficient 
p-value 
Betweenness Centrality 0.266 0.007 
Degree 0.401 0.000032 
PageRank 0.375 0.0001 
 Table 9A. Pearson correlation of three centrality measures from AML 2.1 with 
experimentally obtained 𝜷𝒌 for 101 kinases. 
 
Centrality Measures Spearman Rank Correlation 
Coefficient 
p-value 
Betweenness Centrality 0.234 0.018 
Degree 0.178 0.075 
PageRank 0.158 0.11 
Table 9B. Spearman rank correlation of three centrality measures from AML 2.1 with 
experimentally obtained 𝜷𝒌 for 101 kinases. 
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Kinase targets Average rank Betweenness 
Centrality rank 
KIEN 
rank 
CDK2	   2.5 1 4 
CDK1	   4 7 1 
CDK4	   6 4 8 
CDK6	   9 12 6 
LCK	   10.5 19 2 
LYN	   17.5 20 15 
CHEK1	   18 15 21 
MAP2K2	   18.5 24 13 
RPS6KA1	   18.5 6 31 
CSK	   19 14 24 
Table 10. The top 10 kinase targets identified using the betweenness centrality measure 
from AML 2.1 and the KIEN analysis of experimental data. 
 
 
 
 
Kinase targets Average rank PageRank rank KIEN 
rank 
CDK1	   2 3 1 
CDK2	   2.5 1 4 
CDK4	   5 2 8 
CDK6	   5.5 5 6 
TYRO3	   11 13 9 
CHEK1	   13.5 6 21 
LYN	   14.5 14 15 
CSK	   19.5 15 24 
RPS6KA1	   23.5 16 31 
CHUK	   24 23 25 
Table 11. The top 10 kinase targets identified using the PageRank measure from AML 2.1 
and the KIEN analysis of experimental data. 
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